Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Authors

Talha Munir (ORCID: https://orcid.org/0000-0002-2901-0769)
Deepak Jain (ORCID: https://orcid.org/0000-0001-9476-3671)
Morag Griffin (ORCID: https://orcid.org/0000-0002-4287-0595)
Petra Muus (ORCID: https://orcid.org/0000-0002-2560-3882)
Roochi Trikha (ORCID: https://orcid.org/0009-0009-7273-1463)
Austin Gladston Kulasekararaj (ORCID: https://orcid.org/0000-0003-3180-3570)
Eden Hicks (ORCID: https://orcid.org/0000-0002-4975-4407)
Shreyans Gandhi (ORCID: https://orcid.org/0000-0003-3532-231X)
Richard J. Kelly (ORCID: https://orcid.org/0000-0002-9956-9891)
Ji Yu
Masayo Ogawa

Institutions

King's College London (GB)
Leeds Teaching Hospitals NHS Trust (GB)
St James's University Hospital (GB)
NIHR Wellcome Trust Southampton Clinical Research Facility (GB)
AstraZeneca (United States) (US)
King's College Hospital (GB)

Publication Details

Journal: Haematologica
Published: 2024-11-28
DOI: https://doi.org/10.3324/haematol.2024.285553
Citations: 1
Primary Topic: Complement system in diseases
Type: article
Field-Weighted Citation Impact: 0.24

Funders

AstraZeneca
Alexion Pharmaceuticals

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Talha Munir, Deepak Jain, Morag Griffin, Petra Muus et al.

Nov 28, 2024

1 citations

Haematologica

Complement system in diseases

0.24

article

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Talha Munir, Deepak Jain, Morag Griffin, Petra Muus, Roochi Trikha, Austin Gladston Kulasekararaj, Eden Hicks, Shreyans Gandhi, Richard J. Kelly, Ji Yu, Masayo Ogawa

November 28, 2024article en

1 citations

Abstract

No abstract available for this paper.

HaematologicaVol. 110(4)

King's College London (GB), Leeds Teaching Hospitals NHS Trust (GB), St James's University Hospital (GB), NIHR Wellcome Trust Southampton Clinical Research Facility (GB), AstraZeneca (United States) (US), King's College Hospital (GB)

AstraZeneca, Alexion Pharmaceuticals

Good health and well-being

Openalex Percentile: Top 40%

Complement system in diseases

0.24

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial — Talha Munir, Deepak Jain, et al. · Haematologica (2024) | TGRS Research Map | TGRS